MACC1 and ovarian cancer: The downregulation of MACC1 also decreased phosphorylated (p)ERK1/2 and BCL2 protein levels and upregulated the expression levels of BAD and BAX, making the ovarian cancer cells sensitive towards cisplatin treatment [42].